Castleark Management LLC Increases Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Posted by Geri Gentry on Jun 13th, 2026

Castleark Management LLC boosted its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) by 21.2% during the 4th quarter, HoldingsChannel reports. The firm owned 192,192 shares of the company’s stock after purchasing an additional 33,560 shares during the period. Castleark Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $7,928,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Qube Research & Technologies Ltd lifted its position in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Rubric Capital Management LP lifted its position in Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after purchasing an additional 526,567 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after purchasing an additional 447,536 shares in the last quarter. SG Americas Securities LLC lifted its position in Kiniksa Pharmaceuticals International by 288.6% during the fourth quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock valued at $22,333,000 after purchasing an additional 402,078 shares in the last quarter. Finally, Nomura Holdings Inc. purchased a new position in Kiniksa Pharmaceuticals International during the third quarter valued at $15,421,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider owned 65,623 shares of the company’s stock, valued at approximately $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 2,367 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $48.58, for a total transaction of $114,988.86. Following the completion of the transaction, the chief operating officer directly owned 12,029 shares in the company, valued at $584,368.82. This trade represents a 16.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 653,301 shares of company stock worth $34,046,073 in the last 90 days. Company insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $51.89 on Friday. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $26.27 and a fifty-two week high of $59.87. The firm’s fifty day moving average is $50.50 and its 200 day moving average is $45.94. The stock has a market cap of $3.99 billion, a price-to-earnings ratio of 57.66 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last released its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same quarter in the previous year, the company earned $0.11 EPS. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, equities research analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KNSA shares. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Citigroup lifted their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Finally, Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and an average target price of $60.86.

Get Our Latest Analysis on KNSA

Kiniksa Pharmaceuticals International Company Profile

(Free Report)

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.